A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention".


Journal

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640

Informations de publication

Date de publication:
09 2019
Historique:
received: 25 04 2019
revised: 18 06 2019
accepted: 22 06 2019
pubmed: 27 6 2019
medline: 23 9 2020
entrez: 26 6 2019
Statut: ppublish

Résumé

The public health implications of osteoporosis are enormous but the disease remains underdiagnosed and undertreated. In October 2018, the National Institutes of Health (NIH) convened a Pathways to Prevention (P2P) Workshop entitled "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention" designed to identify research gaps, suggest future research opportunities, and advance the field through an evidence-based assessment. By design, the P2P report focused on "gaps" in our knowledge base. Unfortunately, however, the report did not sufficiently acknowledge the current evidence that unequivocally demonstrates the therapeutic efficacy of existing pharmacologic therapies for osteoporosis, which has the potential to exacerbate the current crises in osteoporosis diagnosis and treatment. © 2019 American Society for Bone and Mineral Research.

Identifiants

pubmed: 31237962
doi: 10.1002/jbmr.3823
pmc: PMC7082897
mid: NIHMS1573495
doi:

Substances chimiques

Bone Density Conservation Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1549-1551

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR027065
Pays : United States

Informations de copyright

© 2019 American Society for Bone and Mineral Research.

Références

J Clin Endocrinol Metab. 2012 Sep;97(9):3097-106
pubmed: 22723322
Bone. 2013 Dec;57(2):423-8
pubmed: 24063946
JAMA. 2009 Oct 14;302(14):1573-9
pubmed: 19826027
Ann Intern Med. 2019 Jul 2;171(1):51-57
pubmed: 31009943
J Bone Miner Res. 2014 Sep;29(9):1929-37
pubmed: 24535775
J Bone Miner Res. 2007 Mar;22(3):465-75
pubmed: 17144789
N Engl J Med. 2012 Nov;367(18):1714-23
pubmed: 23113482
J Bone Miner Res. 2016 Dec 29;32(3):424-430
pubmed: 28099754
J Bone Miner Metab. 2012 May;30(3):321-5
pubmed: 21938382
Osteoporos Int. 2011 May;22(5):1277-88
pubmed: 21461721
Horm Metab Res. 2018 Oct;50(10):738-746
pubmed: 30312984
Osteoporos Int. 2018 Mar;29(3):717-722
pubmed: 29282482
N Engl J Med. 2016 May 26;374(21):2096-7
pubmed: 27223157
J Bone Miner Res. 2014 Nov;29(11):2520-6
pubmed: 24771492

Auteurs

Benjamin Z Leder (BZ)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Bart L Clarke (BL)

Mayo Clinic College of Medicine, Rochester, MN, USA.

Elizabeth Shane (E)

Columbia University College of Physicians and Surgeons, New York, NY, USA.

Sundeep Khosla (S)

Mayo Clinic College of Medicine, Rochester, MN, USA.

Douglas P Kiel (DP)

Harvard Medical School, Musculoskeletal Research Center, Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH